Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Opat

Showing results (91-100 of 133) with videos related to

Pageof 14
Sort By:
Hemasphere|June 19, 2026
Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphomaDavid Belada, Faithlore P Gardner, Ana C de Oliveira, et al.
Blood|March 2, 2026
Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trialJeff P Sharman, Luca Laurenti, Emmanuelle France Ferrant, et al.
Blood|January 3, 2012
Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphomaRobert Kridel, Barbara Meissner, Sanja Rogic, et al.
Internal Medicine Journal|March 7, 2025
Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approachAditya Tedjaseputra, Amanda Tey, Anastasios Nalpantidis, et al.
Cancers|June 10, 2022
Associations between Smoking and Alcohol and Follicular Lymphoma Incidence and Survival: A Family-Based Case-Control Study in AustraliaMichael K Odutola, Marina T van Leeuwen, Jennifer Turner, et al.
Advances in Therapy|July 28, 2022
Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three StudiesWei Xu, Shenmiao Yang, Constantine S Tam, et al.
Blood|July 26, 2019
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLLConstantine S Tam, Judith Trotman, Stephen Opat, et al.
Journal of Hematology & Oncology|October 15, 2021
Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trialsKeshu Zhou, Dehui Zou, Jianfeng Zhou, et al.
Cancer Medicine|September 14, 2023
Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysisYuqin Song, Keshu Zhou, Dehui Zou, et al.
Cancer Epidemiology|September 4, 2022
Associations between early-life growth pattern and body size and follicular lymphoma risk and survival: a family-based case-control studyMichael K Odutola, Marina T van Leeuwen, Jennifer Turner, et al.
Pageof 14

Showing results (91-100 of 133) with videos related to

Sort By:
Pageof 14
Hemasphere|June 19, 2026
Phase 3 PERSPECTIVE study: Ibrutinib with rituximab for initial treatment of patients with follicular lymphomaDavid Belada, Faithlore P Gardner, Ana C de Oliveira, et al.
Blood|March 2, 2026
Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trialJeff P Sharman, Luca Laurenti, Emmanuelle France Ferrant, et al.
Blood|January 3, 2012
Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphomaRobert Kridel, Barbara Meissner, Sanja Rogic, et al.
Internal Medicine Journal|March 7, 2025
Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approachAditya Tedjaseputra, Amanda Tey, Anastasios Nalpantidis, et al.
Cancers|June 10, 2022
Associations between Smoking and Alcohol and Follicular Lymphoma Incidence and Survival: A Family-Based Case-Control Study in AustraliaMichael K Odutola, Marina T van Leeuwen, Jennifer Turner, et al.
Advances in Therapy|July 28, 2022
Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three StudiesWei Xu, Shenmiao Yang, Constantine S Tam, et al.
Blood|July 26, 2019
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLLConstantine S Tam, Judith Trotman, Stephen Opat, et al.
Journal of Hematology & Oncology|October 15, 2021
Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trialsKeshu Zhou, Dehui Zou, Jianfeng Zhou, et al.
Cancer Medicine|September 14, 2023
Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysisYuqin Song, Keshu Zhou, Dehui Zou, et al.
Cancer Epidemiology|September 4, 2022
Associations between early-life growth pattern and body size and follicular lymphoma risk and survival: a family-based case-control studyMichael K Odutola, Marina T van Leeuwen, Jennifer Turner, et al.
Pageof 14